Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Generics Office Drinks Super Serum, Then Shrinks

Executive Summary

OGD sheds almost half its staff as part of an organizational elevation.

You may also be interested in...



New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges

The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.

US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role

The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.

Generics Office At US FDA Could Get New Director Before Uhl Departs

Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS055805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel